他莫昔芬预构米色脂肪组织提高小鼠脂肪移植存活率
研究将C57/BL6小鼠分三组,比较他莫昔芬预处理联合移植后用药、仅移植后用药与对照组的脂肪移植效果。结果显示他莫昔芬预处理组移植脂肪保留率显著高于对照组(69±12% vs 36±13%,p<0.05),而仅移植后用药组与对照组相似(31±12% vs 36±13%,p>0.05)。结论为他莫昔芬移植前处理可预构血管化米色脂肪并大幅改善移植存活,移植后给药则不影响脂肪演化。
要点
- 他莫昔芬预处理8周使腹股沟脂肪呈米色脂肪特征,脂肪细胞更小、UCP1表达上调、血管化改善。
- 他莫昔芬/移植/他莫昔芬组脂肪保留率69±12%,显著高于对照组36±13%(p<0.05)。
- 移植/他莫昔芬组保留率31±12%,与对照组36±13%相似(p>0.05),移植后给药不影响脂肪演化。
核心结论
- 脂肪移植前给予他莫昔芬可预构出血管化的米色脂肪(脂肪细胞小),大幅提高脂肪移植存活率;但脂肪移植后给予他莫昔芬不影响脂肪移植物演化。
研究设计与样本
- C57/BL6小鼠分为三组,比较移植前后不同处理对脂肪移植的影响。
- 他莫昔芬/移植/他莫昔芬组:每日他莫昔芬预处理8周,行脂肪移植,移植后每日他莫昔芬。
- 移植/他莫昔芬组:每日磷酸盐缓冲液预处理8周,行脂肪移植,移植后每日他莫昔芬。
- 对照组:每日磷酸盐缓冲液预处理8周,行脂肪移植,移植后每日磷酸盐缓冲液。
- 取移植用腹股沟脂肪及移植后第4周和第12周的转移脂肪进行分析。
主要发现
- 他莫昔芬预处理的腹股沟脂肪呈米色脂肪特征,脂肪细胞尺寸更小、解偶联蛋白1表达上调、血管化改善。
- 他莫昔芬/移植/他莫昔芬组转移脂肪保留率显著高于对照组(69±12% vs 36±13%,p<0.05)。
- 移植/他莫昔芬组脂肪移植物保留率与对照组相似(31±12% vs 36±13%,p>0.05)。
- 他莫昔芬/移植/他莫昔芬组可见血管生成改善和血管内皮生长因子表达增加,而移植/他莫昔芬组未见。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fat grafting has become an important tool for breast reconstruction in breast cancer patients. Tamoxifen, the hormone therapy agent most frequently used for breast cancer, can affect adipose metabolism and cause browning of adipose tissue. This study hypothesized that tamoxifen could increase fat graft survival by altering adipose metabolism. METHODS: C57/BL6 mice were divided into three groups receiving different treatments before and after fat grafting. The tamoxifen/grafting/tamoxifen group was pretreated with daily tamoxifen for 8 weeks, received fat grafting, and was treated with daily tamoxifen. The graft/tamoxifen group was pretreated with daily phosphate-buffered saline for 8 weeks, received fat grafting, and was treated with daily tamoxifen. The control group was pretreated with daily phosphate-buffered saline for 8 weeks, received fat grafting, and was treated with daily phosphate-buffered saline. The inguinal fat used for transplantation and the transferred fat at weeks 4 and 12 after transplantation were harvested and analyzed. RESULTS: Tamoxifen-pretreated inguinal fat showed beige fat features, with smaller adipocyte size, up-regulated uncoupling protein 1 expression, and improved vascularization. The retention rate of transferred fat was significantly higher in the tamoxifen/grafting/tamoxifen group than in the control group (69 ± 12 percent versus 36 ± 13 percent; p < 0.05), but fat grafts in the graft/tamoxifen group had a retention rate similar to that in the control group (31 ± 12 percent versus 36 ± 13 percent; p > 0.05). Improved angiogenesis and increased vascular endothelial growth factor expression were found in the tamoxifen/grafting/tamoxifen group but not in the graft/tamoxifen group. CONCLUSIONS: Tamoxifen treatment before fat grafting resulted in prefabricated vascularized beige fat with small adipocytes, which greatly improve fat graft survival. However, tamoxifen after fat grafting did not affect fat graft evolution.
引用
- Cai J, Li B, Wang J, et al. Tamoxifen-Prefabricated Beige Adipose Tissue Improves Fat Graft Survival in Mice. Plast Reconstr Surg. 2018. PMID: 29256999. doi:10.1097/PRS.0000000000004220
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。